2 promising small-cap stocks that could be millionaire-makers in 2018

These two shares could help you to generate high returns.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Finding the best stocks at the lowest prices is never easy. However, even though the FTSE All-Share has risen significantly in recent years, there may still be investment opportunities. One sector that could offer high returns is healthcare, with a growing ageing world population providing a potential tailwind.

With that in mind, here are two stocks which could deliver rising share prices in future. As such, they could be worth buying today.

Improving performance

Reporting on Monday was US healthcare market Value Cycle solutions specialist, Craneware (LSE: CRW). The company announced that it has continued to perform strongly in the first half of the year, with its growth strategy successfully executed. Renewals by dollar value have continued at over 100% during the period. It now expects to report an increase in both revenue and adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) of between 15% and 18% for the six months to the end of December 2017.

The company also reported a significant contract win on Monday that’s expected to deliver in excess of $16m of revenue over its initial five-year term. This could prove to be a positive catalyst for a company which has been able to deliver double-digit earnings growth in the last three financial years. This consistently high growth in profitability could show that Craneware is worthy of a premium valuation in the long run.

With the stock currently trading on a price-to-earnings (P/E) ratio of around 38, it seems to be popular among investors. While there may not be scope for a significantly higher rating, the stock’s earnings growth potential remains high. This could propel its share price upwards in the long run.

Upbeat outlook

Also offering growth potential in the healthcare sphere is Alliance Pharma (LSE: APH). The acquirer and licensor of pharmaceutical products has a long track record of delivering growth. It has been able to do so in four of the last five financial years, and this trend looks set to continue over the medium term. In fact, the company is forecast to record a 15% rise in 2018 earnings, which could cause investor sentiment to improve significantly.

Despite a rise in its share price of 38% in the last year, Alliance Pharma trades on a price-to-earnings growth (PEG) ratio of just 1. This suggests it offers a wide margin of safety, which could lead to a higher rating in the long term.

With the company having a stable growth outlook, it may also be seen as a relatively defensive stock. Certainly, it appears to lack a high degree of positive correlation with the wider index and with the economy. This could help investors to diversify at a time when the political risk facing the UK continues to build. As such, now could be the perfect time to buy the stock for the long term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares in Alliance Pharma and Craneware. The Motley Fool UK has recommended Craneware. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 14% in 2024, what’s next for the Lloyds share price?

This Fool takes a closer look at what prompted the Lloyds share price to rise this year, and offers her…

Read more »

Investing Articles

5 FTSE 100 stocks to consider for a lifetime of passive income

I see lots of cheap dividend stocks in the FTSE 100 right now, but prices are starting to rise. Here's…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

3 growth stocks I’m desperate to buy as the FTSE 100 dips

Never waste a dip, says Harvey Jones. Three of his favourite growth stocks have fallen over the last month and…

Read more »

Investing Articles

I’d use a £10K ISA to try and generate £900 in dividends annually like this!

Christopher Ruane explains how he would invest a Stocks and Shares ISA in blue-chip companies to try and set up…

Read more »

Investing Articles

Here’s how I’d build a second income stream worth £1,228 a month by investing £10 a day!

A second income stream could come in handy later in life. This Fool explains how she’d build one by investing…

Read more »

Investing Articles

5 FTSE 250 stocks I’d buy for a lifetime of passive income

Here's why I think the FTSE 250 could be the best UK stock market index to go for in 2024…

Read more »

Union Jack flag triangular bunting hanging in a street
Investing Articles

Buy cheap FTSE shares, says HSBC

Analysts at HSBC have upgraded their rating of FTSE stocks and reckon the blue-chip UK index could carry on powering…

Read more »

Couple working from home while daughter watches video on smartphone with headphones on
Investing Articles

It could be worth buying the dip for this FTSE 250 stock, down 7% today

Jon Smith spots a sharp drop in a FTSE 250 stock but explains why this could just be a blip…

Read more »